CSPC Pharmaceutical Group (01093.HK): Updated overall survival (OS) results from the Phase III clinical study of anbenitamab for the treatment of HER2-positive advanced gastric/gastroesophageal junction adenocarcinoma were presented in a rapid oral presentation at the 2026 ESMO Congress

Zhitong Finance APP News, CSPC Pharmaceutical Group (01093.HK) announced that the updated overall survival (OS) analysis results of the Phase III clinical study (Study No.: KC-WISE) of Anntoizumab Injection (trade name: Ennto), jointly developed by the Group and Jiangsu Alphamab Biopharmaceuticals Co., Ltd., in combination with chemotherapy for the treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced gastric/gastroesophageal junction adenocarcinoma (GC/GEJA) in patients who had previously failed trastuzumab treatment, were selected as a Late-breaking Abstract (LBA) at the 2026 European Society for Medical Oncology (ESMO) Annual Congress on October 23, 2026, and were presented in a rapid oral presentation format.